(NASDAQ: BLRX) Biolinerx's forecast annual revenue growth rate of -41.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Biolinerx's revenue in 2025 is $22,340,000.On average, 2 Wall Street analysts forecast BLRX's revenue for 2025 to be $4,978,702,438, with the lowest BLRX revenue forecast at $3,706,119,303, and the highest BLRX revenue forecast at $6,251,285,572. On average, 1 Wall Street analysts forecast BLRX's revenue for 2026 to be $17,168,709,303, with the lowest BLRX revenue forecast at $17,168,709,303, and the highest BLRX revenue forecast at $17,168,709,303.
In 2027, BLRX is forecast to generate $28,465,675,373 in revenue, with the lowest revenue forecast at $28,465,675,373 and the highest revenue forecast at $28,465,675,373.